“…Computational tools already exist to facilitate drug candidate screening by the identification of sequence liabilities 6 , 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45. In the case of asparagine deamidation, 36 , 40, 41, 42, 43, 44, 45 currently available tools suffer from several limitations: they provide only a binary (yes, high risk to deamidate; or no, low risk to deamidate) prediction, 36 , 40 , 42 , 43 require an experimental crystal structure,42, 43, 44, 45 or are applicable only to antibody asparagines 36 , 40 .…”